This trial is part of the company’s comprehensive development program in NHL, which represents a significant growth opportunity for Velcade. The primary endpoint of the open-label trial is complete remission with secondary endpoints including progression free survival and duration of remission. The trial is expected to enroll approximately 75 patients.
Nancy Simonian, chief medical officer of Millennium, said: “We designed this trial to combine three active agents in NHL with the goal of enhancing the clinical outcomes of this patient population. We are hopeful this novel combination will add to the growing body of data that show the potential of Velcade to be part of the standard of care in follicular lymphoma, similar to what we’ve seen in multiple myeloma.”